Neoimmune Tech is concluding its share consolidation procedure, and the temporarily suspended stock trading will resume on the upcoming 10th.

The Korea Exchange announced through a disclosure on the 9th that it will implement the revised listing for Neoimmune Tech due to the share consolidation on June 10, 2026. Neoimmune Tech is a U.S. corporation, and this revised listing follows a 5-to-1 share consolidation. Accordingly, the par value based on the underlying shares will be adjusted from 0.0001 USD per share pre-consolidation to 0.0005 USD post-consolidation. Although the number of underlying shares decreases and the par value increases due to the share consolidation, there is no change to the company's实质性 corporate value, and the dividend commencement date also remains unchanged at January 1, 2026.

The company's common stock is entirely listed on the Korea Exchange in the form of DRs (Depositary Receipts), with a structure issuing 5 DR shares per 1 underlying share. Due to this consolidation, the number of issued shares based on the underlying shares decreased from 33,527,880 shares to 6,705,576 shares. However, following the revised listing, the total number of listed shares will be maintained at the previous 33,527,880 shares based on KDR.

Meanwhile, the Korea Exchange plans to lift the trading suspension of Neoimmune Tech's KDRs, which was implemented due to this revised listing, on the 10th. However, since off-hours trading will not be executed prior to the market opening on the 10th, the trading resumption date, in accordance with relevant regulations, investors are advised to exercise caution.